Open company graph database — free web & API
Login

Shionogi Business Partner Co., Ltd.

シオノギビジネスパートナー株式会社SHIONOGI BUSINESS PARTNER CO., LTD.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
274
Related companies
23
§01

Basic information

BASIC
Head office
Shionogi Michishiocho Building, 4-7-6 Michishiocho, Chuo-ku, Osaka, 541-0045
Chief executive
Yuuji Hosokawa
Capital
10,000,000 JPY
Employees (non-consolidated)
Employees (consolidated)
274 people
Start date
2017-04-03
End date
§02

Websites

1 DOMAINS
§03

Business

0
§04

Related companies

23 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Shionogi Healthcare Co.,Ltd.
Group
Shionogi Smile Heart Co.,Ltd.
Group
Shionogi Smile Heart Co., Ltd.
Group Subsidiary
Shionogi Pharma Co., Ltd.
Group Subsidiary
Shionogi Healthcare Co., Ltd.
Group Subsidiary
UMN Pharma Co., Ltd.
Group
Shionogi & Co., Ltd.
Group Customer
Burn foundation of America
Group
Gloridge
Group
V:DRIVE
Group
Verizon社
Group
Accenture Corporation
Group
キープ・ママ・スマイリング
Group
シオノギキャリア開発センター株式会社
Group
モリス郡異宗教間フードパントリー ネットワーク
Group
全国食支援活動協力会
Group
秋田市医師会
Customer
秋田県医師会
Customer
Suntory
Supplier
Asahi Group Japan subsidiary, Asahi Beverage Co., Ltd.
Supplier
General Incorporated Association Japan Foundation Telephone Relay Service
Supplier
Oil Japan Agro Research Co., Ltd.
Supplier
Shionogi Inc.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

64 EVENTS

Shionogi Saburo founded the Shionogi Saburo Store in Michishiocho, Osaka, selling traditional Japanese and Western medicines.Sources

On March 17, 1878, on his 24th birthday, he established the pharmaceutical wholesaler 'Shionogi Saburo Shoten' at 3-12 Dousho-cho, Osaka.Sources

Shifted product line to Western medicines.Sources

Eight years after founding, in 1886, when Western medicine began to spread widely, the company started importing and selling Western drugs.Sources

Commenced direct transactions with Western trading companies.Sources

Manufactured and sold the first in-house antacid 'Antacidin', trademark registered with the 'Bento' mark.Sources

In 1909, following the graduation of Shionogi Saburo's second son, Nagajiro, from the Pharmaceutical Department of Tokyo Imperial University, SHIONOGI began serious pharmaceutical research. Nagajiro started trial production of the antacid, successfully commercialized it. This stomach-protecting antacid 'Antachijin' became the first self-developed new drug at Shionogi Saburo Shoten.Sources

In 1909, the balance mark was registered as a trademark. SHIONOGI's symbol is derived from the 'balance weights' used when measuring medicine on a scale.Sources

Construction of Shionogi Pharmaceutical Plant in Fukushima-ku, Osaka.Sources

In 1910, a new pharmaceutical factory 'Shionogi Pharmaceutical Factory' was built in Nishinari-gun, Osaka Prefecture (now Fukushima-ku, Osaka City), and began full operation in 1910.Sources

Merged Shionogi Saburo Store and Shionogi Pharmaceutical Plant, reorganized into Shionogi Shoten Co., Ltd.Sources

Established Kuse Factory in Amagasaki, Hyogo Prefecture (now Kuse Office), and set up a laboratory within the factory.Sources

Built a new headquarters building in Michishiocho, Osaka.Sources

Changed company name to Shionogi Pharmaceutical Co., Ltd.Sources

In 1943, the company changed its name to Shionogi Yoshiharu Pharmaceutical Co., Ltd.Sources

In 1945, rapid hyperinflation after the war, escalating price increases caused chaos, frozen corporate deposits, and termination of wartime compensation, leading SHIONOGI to become nearly bankrupt and fall into the worst management condition since its founding.Sources

Established Yudin Farm in Shiga Prefecture (now Yudin Office).Sources

Listed on the Tokyo and Osaka Stock Exchanges.Sources

Release of analgesic 'Sedus'.Sources

In 1950, the analgesic 'Sedes' was launched.Sources

Release of comprehensive vitamin 'Popon S'.Sources

Establishment of basic policy.Sources

Discovery of Shinomine: Established the Detailman system.Sources

Release of sulfa drug 'Shinomine'.Sources

Constructed Central Research Institute in Fukushima-ku, Osaka (now consolidated into the Pharmaceutical Research Center).Sources

Established Animal Pharmaceutical Division (transferred in 2002), Plant Pharmaceutical Division (transferred in 2001), commenced clinical laboratory operations (transferred in 2002): Established Taiwan Shionogi Pharmaceutical (Ltd.).Sources

Broadcast of the company-provided program 'Shionogi Music Fair' commenced.Sources

Constructed Settsu Factory in Settsu City, Osaka Prefecture.Sources

Established Shionogi Pharmaceutical Co., Ltd. (now Shionogi Pharma Co., Ltd.)Sources

Constructed Shionogi Shibuya Building (Shibuya-ku, Tokyo) and New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Medical Research Center)Sources

Launch of oxacyl antibiotic 'Shiomarin'Sources

Constructed Kanegasaki Factory (Iwate Prefecture)Sources

Constructed Medical Science Research Institute within Settsu plant site (now consolidated into Medical Research Center) and launched oxacyl antibiotic 'Fullmarin'Sources

Established Shionogi Comprehensive Services Co., Ltd. (now Shionogi Business Partner Co., Ltd.) and acquired capsule business from Eli Lilly (sold in 2005)Sources

Constructed New Headquarters Building (Michi-shu-cho, Osaka City)Sources

Launch of cephalosporin antibiotic 'Fromax'Sources

Adopted Shionogi Code of Conduct (revised 2012), established Oomori Pharmaceutical Co., Ltd. (sold 2002), and established Bushu Pharmaceutical Co., Ltd. (sold 2010)Sources

Start of First Medium-Term Management PlanSources

From April 2000 to March 2005, to consolidate the pharmaceutical business, we transferred the sales of botanical medicines, veterinary medicines, and pharmaceutical wholesale to other companies.Sources

Established Shionogi USA, Inc. (now Shionogi Inc.) and international JV Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC) to begin joint research and development of HIV treatment drugsSources

Launch of cancer pain medication 'Oxycontin'Sources

Start of Second Medium-Term Management Plan, launch of cholesterol-lowering drug 'Crestor', and launch of carbapenem antibiotic 'Finibax'Sources

From April 2005 to March 2010, in pursuit of narrowing research areas and accelerating development, we established a development subsidiary in the United States in 2001, and also began joint development of new drugs with GlaxoSmithKline in the United Kingdom.Sources

Established Shionogi Analytical Center Co., Ltd. and launched oral cancer pain medication 'Okinome'Sources

Acquired U.S. Sciele Pharma, Inc. (now Shionogi Inc.) and established Shionogi Drug Discovery Innovation Center in collaboration with Hokkaido University; launched hypertension drug 'Ilbetan', acne treatment drug 'Deferin', and idiopathic pulmonary fibrosis drug 'Pirespa'Sources

Start of Third Medium-Term Management Plan, established Shionogi Techno Advance Research Co., Ltd., opened Osaka University Graduate School of Medicine PET Molecular Imaging Center, launched influenza antiviral drug 'Rapiacta', and launched antidepressant 'Sainbarta'Sources

From April 2010 to March 2014, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited in 2011, and established the development subsidiary Shionogi Limited in the United Kingdom in 2012, thereby advancing our basic policy of globalization.Sources

Acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Ltd. and constructed new SPRC4 building within Medical Research Center (SPRC) to consolidate drug discovery research functionsSources

Established European subsidiary Shionogi Limited (UK), signed new framework agreement with Vibe Healthcare regarding HIV treatment drugs, launched cancer pain injection 'OkiFast', and launched hypertension drug 'Aimix'Sources

Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China) and Shionogi Singapore Pte. Ltd.; changed royalty agreement on Crestor with AstraZeneca; launched postmenopausal vaginal atrophy drug 'Osphena' in the U.S.; launched hypertension drug 'Iltra'Sources

Start of Medium-Term Management Plan 'Shionogi Growth Strategy 2020 (SGS2020)', launched HIV treatment drug 'Tebikei'Sources

In April 2014, the new medium-term management plan set the vision of 'growing as a drug discovery-oriented pharmaceutical company', defined ROE (return on equity) as one of the management indicators, clarified the items to be accomplished over the next three years, and clearly indicated that we would work toward the 2020 management goal by reviewing results and challenges annually on a rolling basis.Sources

Launch of the HIV treatment drug 'Trimek' : Launch of the allergen immunotherapy drug 'Asithea' : Launch of the thrombocytopenia treatment drug 'Mulpleta'Sources

Update of the mid-term management plan 'SGS2020' : Establishment of Shionogi Healthcare Co., Ltd. : Launch of the high cholesterol treatment drug 'Crestol OD tablets'Sources

Establishment of domestic group companies: Shionogi Career Development Center Inc., Shionogi Digital Science Inc., Shionogi Business Partner Inc., Shionogi Pharma Pharmacovigilance Center Inc., Shionogi Marketing Solutions Inc. : Launch of the cancer pain treatment drug 'Mesapain' : Launch of the ADHD treatment drug 'Intunib' : Launch of the opioid-induced constipation treatment drug 'Symproic' in the United States : Launch of the opioid-induced constipation treatment drug 'Soinproik' : Launch of the sustained cancer pain treatment drug 'Oxycontin TR tablets'Sources

Establishment of Shionogi Pharma Inc. : Establishment of European subsidiary Shionogi B.V. : Launch of the anti-influenza virus drug 'Zoflura' : Launch of the thrombocytopenia treatment drug 'Mulpleta' in the United States : Launch of the anti-HIV drug 'Jaruka'Sources

Establishment of the joint venture company 'Stream-I Co., Ltd.' with M3 Inc. : Consolidation of UMN Pharma Inc. as a subsidiary : Opening of the Shionogi Education and Training Center in Amagasaki City : Launch of the opioid-induced constipation treatment drug 'Rizmoic' in Europe : Launch of the anti-influenza virus drug 'Shufukou' in Taiwan : Launch of the ADHD treatment drug 'Vivance'Sources

Launch of the mid-term management plan 'Shionogi Transformation Strategy 2030 (STS2030)' : Establishment of the joint venture company 'Ping An Shionogi Co., Ltd.' with China Ping An Insurance : Full acquisition of Tetra Inc. in the United States : Acquisition of Nagase Pharmaceutical as a subsidiary by Shionogi Pharma : Launch of the gram-negative bacterial infection treatment drug 'Fetroja' in the United States : Launch of the gram-negative bacterial infection treatment drug 'Fetcroja' in EuropeSources

Launch of the sewage ecology survey service for COVID-19 : Launch of the opioid-induced constipation treatment drug 'Soinproik' in TaiwanSources

Establishment of the joint venture company 'AdvanSentinel Co., Ltd.' with Shimadzu CorporationSources

Establishment of the General Incorporated Foundation 'Shionogi Infectious Disease Research Promotion Foundation'Sources

Construction of the SHIONOGI Group brand and establishment of the group brand markSources

Establishment of Yui Connection Co., Ltd.Sources

Launch of the COVID-19 treatment drug 'Zocova'Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information8120001204745
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
シオノギビジネスパートナー株式会社
Trade name (kana)
シオノギビジネスパートナー
Name in English
Corporation type
301
Address
〒541-0045 大阪府大阪市中央区道修町4丁目7番6号
Postal code
5410045
Prefecture code
27
City code
128
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2017-04-12
Update date
2023-07-07
Change date
2023-07-03
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和5年7月1日大阪市中央区道修町四丁目7番6号シオノギファーマコビジランスセンター株式会社(6120001204747)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
0
Trade name image ID
Address image ID
Sequence number
4370246
METI gBizINFO8120001204745
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8120001204745
Trade name
シオノギビジネスパートナー株式会社
Trade name (kana)
シオノギビジネスパートナー
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市中央区道修町4丁目7番6号
Postal code
5410045
Prefecture
大阪府
Prefecture code
27
City or district
大阪市中央区
City code
128
Street address
道修町4丁目7番6号
Organisation type
301
Processing type
71
Correction type
0
Status
Representative
Capital
Employees
268
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
R:サービス業(他に分類されないもの)
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-07-07
Key information
8120001204745
§09

Sources & updates

SOURCES
↑